Abstract
Aim: To estimate financial implications of adopting niraparib as maintenance treatment in recurrent ovarian cancer. Materials & methods: A model was developed to estimate the budget impact of treating patients with niraparib compared with alternative maintenance treatment options (olaparib, rucaparib, bevacizumab or 'watch and wait') over 3 years. Results: For a hypothetical plan with 1 million lives representative of US/Medicare-only populations, projected cost savings with niraparib were US$78,721/$293,723, $276,671/$1,009,729 and $353,585/$1,289,712 at years 1, 2 and 3, respectively. Sensitivity analyses showed prices of niraparib, rucaparib and olaparib to have the most significant impact on the budget. Conclusion: Factoring in all treatment-related costs, the use of niraparib could result in significant cost savings compared with other maintenance treatment options.
Keywords:
PARP inhibitors; USA; budget impact analysis; costs; economics; maintenance therapy; recurrent ovarian cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents / economics*
-
Antineoplastic Agents / therapeutic use
-
Budgets*
-
Carcinoma, Ovarian Epithelial / drug therapy
-
Carcinoma, Ovarian Epithelial / economics*
-
Clinical Trials as Topic
-
Drug Costs
-
Drug Substitution / economics
-
Female
-
Humans
-
Indazoles / economics*
-
Indazoles / therapeutic use
-
Indoles / economics
-
Indoles / therapeutic use
-
Medicare / economics
-
Models, Economic
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / economics
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / economics*
-
Phthalazines / economics
-
Phthalazines / therapeutic use
-
Piperazines / economics
-
Piperazines / therapeutic use
-
Piperidines / economics*
-
Piperidines / therapeutic use
-
Platinum Compounds / economics
-
Platinum Compounds / therapeutic use
-
Poly(ADP-ribose) Polymerase Inhibitors / economics*
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
-
United States
Substances
-
Antineoplastic Agents
-
Indazoles
-
Indoles
-
Phthalazines
-
Piperazines
-
Piperidines
-
Platinum Compounds
-
Poly(ADP-ribose) Polymerase Inhibitors
-
rucaparib
-
niraparib
-
olaparib